Faes Farma (FAE) Q1 2025 earnings summary

Executive summary

• Total income rose 9.7% year-over-year, reaching the high end of guidance, driven by 14% growth in the three strategic molecules.

• Pharma income increased 8%, with LATAM up 19% and Licences up 12% as main growth drivers.

• Adjusted EBITDA grew 3% excluding Derio's one-off costs; reported EBITDA declined 4.1%.

• Net profit decreased 6.8% year-over-year to €28.4M.

• Strategic developments included approval of pediatric bilastine in Europe, submission of mesalazine dossier, and acquisition of Laboratorios Edol.

Financial highlights

• Total income: €153.0M (+9.7% YoY); Pharma income: €136.3M (+8% YoY).

• EBITDA: €39.3M (-4.1% YoY); Adjusted EBITDA: €42.2M (+3% YoY, excluding Derio costs).

• Net profit: €28.4M (-6.8% YoY); EBIT: €33.7M (-6.3% YoY).

• Animal Nutrition and Health income: €16.7M (+29% YoY).

• Top 3 molecules income: €66.7M (+14.5% YoY).

Outlook and guidance

• 2025 income expected to grow 8–10% year-over-year.

• 2025 EBITDA projected to decline 6–9% year-over-year due to transition costs; adjusted EBITDA expected to rise 3–5%.